




RealRate

PHARMACEUTICAL 2019

Neuropathix INC
Rank 171 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Neuropathix INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neuropathix INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Neuropathix INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 277%, being 27% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	3,003
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	546
Liabilities, Non-Current	1,146
Other Assets	17
Other Compr. Net Income	0
Other Expenses	812
Other Liabilities	0
Other Net Income	2,805
Other Revenues	174
Property and Equipment	3.1
Research and Development	225
Selling, General and Administrative Expense	1,011

Output Variable	Value in 1000 USD
Assets	3,023
Liabilities	1,692
Expenses	2,048
Revenues	174
Stockholders Equity	1,331
Net Income	931
Comprehensive Net Income	931
BaseVar	4,871
ECR before LimitedLiability	163%
Economic Capital Ratio	277%